Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-05-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520
combined with lenvatinib in the treatment of patients with advanced solid tumors. About
138~158 patients with advanced solid tumors plan to be enrolled in about 30 study sites of
the study.
Part I: Phase Ib study evaluating the safety and tolerability of F520 combined with
lenvatinib in patients with advanced solid tumors.
Part II: Phase II study of F520 combined with lenvatinib in endometrial cancer and cervical
cancer.